Halliburton (HAL), Schlumberger (SLB) and Baker Hughes (BHI). Three oil services firms with three very different responses to news today.
BloombergFirst up, Halliburton. It reported a profit of 93 cents a share, above forecasts for 89 cents, yet Halliburton’s shares have dropped 1.8% to $49.76. Citigroup’s Robin Shoemaker and Mark Brown explain why:
…the stock is trading lower today largely because the company cited several negative factors that are impacting its Latin America operations in 2014…
The major challenge comes from Brazil, where offshore drilling activity fell in 2013 and is expected to decline further in 2014. Halliburton won a large multi-year drilling services contract from�Petrobras (PBR) before offshore activity began to slow. After putting in place the people and infrastructure to execute the contract, [Halliburton] has been very disappointed with the volume of drilling services work that Petrobras� has needed under the terms of the contract…
10 Best Canadian Stocks To Own Right Now: Monsanto Co (MON)
Monsanto Company (Monsanto), incorporated on February 9, 2000, along with its subsidiaries, is a provider of agricultural products for farmers. The Company's seeds, biotechnology trait products, and herbicides provide farmers with solutions that improve productivity, reduce the costs of farming, and produce better foods for consumers and better feed for animals. It manages business in two segments: Seeds and Genomics, and Agricultural Productivity. In April 2010, the Company completed the acquisition of a corn and soybean processing plant located in Paine, Chile from Anasac, a company that provides seed processing services. In October 2009, the Company completed the acquisition of Seminium, S.A. (Seminium), a corn seed company. In February 2011, the Company acquired Divergence, Inc. In September 2011, the Company acquired Beeologics. In June 2012, the Company purchased a planting technology developer, Precision Planting, Inc. In January 2013, it purchased select assets of Agradis, Inc. In June 2013, Monsanto Company acquired GrassRoots Biotechnology Inc. In November 2013, the Company announced that it has completed the acquisition of The Climate Corporation.
Seeds and Genomics Segment
Through the Company's Seeds and Genomics segment, it produces seed brands, including DEKALB, Asgrow, Deltapine, Seminis and De Ruiter, and it develops biotechnology traits that assist farmers in controlling insects and weeds. It also provides other seed companies with genetic material and biotechnology traits for their seed brands. It has a global distribution and sales and marketing organization for its seeds and traits. It sells products under Monsanto brands and license technology and genetic material to others for sale under their own brands. Through distributors, independent retailers and dealers, agricultural cooperatives, plant raisers, and agents, it markets DEKALB, Asgrow and Deltapine branded germplasm to farmers globally. In the United States, it markets regional seed brands under it! s American Seeds, LLC and Channel Bio, LLC businesses to farmers directly, as well as through dealers, agricultural cooperatives and agents. It markets and sells trait technologies with branded germplasm, pursuant to license agreements with its farmer customers. In Brazil and Paraguay, its has implemented a point-of-delivery, grain-based payment system. It contracts with grain handlers to collect applicable trait fees when farmers deliver their grain. In addition to selling its products under its own brands, the Company licenses a range of germplasm and trait technologies to large and small seed companies in the United States and certain international markets. Those seed companies in turn market its trait technologies in their branded germplasm; they may also market its germplasm under its own brand name. Its vegetable seeds are marketed in more than 100 countries through distributors, independent retailers and dealers, agricultural cooperatives, plant raisers and agents, as well as directly to farmers.
The Company�� row crop seeds brands include DEKALB, Channel Bio, Asgrow and Deltapine. Its DEKALB and Channel Bio are corn hybrids and foundation seed. Its Asgrow are soybean varieties and foundation seed. Its Deltapine are cotton varieties, hybrids and foundation seed. Canola is its row crop variety and hybrid. Its vegetable seed brands are Seminis and De Ruiter. These are open field and protected-culture seed for tomato, pepper, eggplant, melon, cucumber, pumpkin, squash, beans, broccoli, onions, and lettuce, among others. Its Biotechnology traits include SmartStax, YieldGard, YieldGard VT Triple, VT Triple PRO, VT Double PRO, Roundup Ready and Roundup Ready 2 Yield and Genuity. Its SmartStax, YieldGard, YieldGard VT Triple, VT Triple PRO and VT Double PRO have applications for corn, and Bollgard and Bollgard II have application for cotton. It enables crops to protect themselves from borers and rootworm in corn and leaf- and boll-feeding worms in cotton, reducing the need for application! s of inse! cticides. Its Roundup Ready and Roundup Ready 2 Yield have application for soybeans. The Company�� Genuity is a global umbrella trait brand. It enables crops, such as corn, soybeans, cotton, and canola to be tolerant of Roundup and other glyphosate-based herbicides. Monsanto also offers farmers stacked-trait products, which are single-seed products in which two or more traits are combined.
Agricultural Productivity Segment
Through the Company's Agricultural Productivity segment, it manufactures Roundup brand herbicides and other herbicides and provide lawn-and-garden herbicide products for the residential market. Its products include Glyphosate-based herbicides, Selective herbicides and Lawn-and-garden herbicides. Its Glyphosate-based herbicides have applications in nonselective agricultural, industrial, ornamental and turf applications for weed control. Its Selective herbicides control preemergent annual grass and small seeded broadleaf weeds in corn and other crops. Its residential lawn-and-garden has applications for weed control. It uses the same distribution and sales and marketing organization for its crop protection products as for its seeds and traits. It also has separate distribution and sales and marketing organizations for its crop protection products. It sells crop protection products through distributors, independent retailers and dealers and agricultural cooperatives. In some cases outside the United States, it sells such products directly to farmers. It also sells certain of the chemical intermediates of its crop protection products to other agricultural chemical producers, who then market their own branded products to farmers. The Company markets its lawn-and-garden herbicide products through The Scotts Miracle-Gro Company.
Advisors' Opinion:- [By Rich Bieglmeier]
[Related -Should Monsanto Company's (MON) Stock Belong In Your Portfolio?]
Sales, like earnings, are expected to rise 6.2% year-over-year. Monsanto's consensus revenue estimate for Q2 is $5.81 billion, up from last year's $5.47 billion.
Top 5 Oil Service Companies For 2015: Ishares S&P 500 (IVV)
iShares Core S&P 500 ETF, formerly iShares S&P 500 Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of United States large-cap stocks, as represented by the Standard & Poor�� 500 Index (the Index). The Index measures the performance of the large-capitalization sector of the United States equity market. The Index serves as the underlying index for the S&P 500/Citigroup Growth and Value Index series.
The Index is a capitalization-weighted index from a range of industries chosen for market size, liquidity and industry group representation. The component stocks are weighted according to the total float-adjusted market value of their outstanding shares. The Index is adjusted to reflect changes in capitalization resulting from mergers, acquisitions, stock rights, substitutions and other capital events. The Fund�� investment advisor is Barclays Global Fund Advisor.
Advisors' Opinion:- [By John Udovich]
One of the most famous scenes in the cult classic, the Graduate, was when Mr. McGuire�took Dustin Hoffman�� character aside and said�"Ben, I want to say one word to you, just one word: Plastics"; but what about the Berry Plastics Group Inc (NYSE: BERY) and its performance verses that of the�iShares S&P 500 Index ETF (NYSEARCA: IVV), iShares Russell Midcap Index Fund ETF (NYSEARCA: IWR) and iShares S&P SmallCap 600 Index ETF (NYSEARCA: IJR)? I should mention that plastics and the Berry Plastics Group was not the place to be yesterday as the stock took a tumble on reduced guidance.
- [By Dan Caplinger]
Moreover, during extremely bullish periods, investors tend to drive up shares of investment management companies. Take a look at how BlackRock stock has performed over the past six months, compared to shares of its two largest ETFs, iShares Core S&P 500 (NYSEMKT: IVV ) and iShares MSCI Emerging Markets (NYSEMKT: EEM ) :
Top 5 Oil Service Companies For 2015: Mast Therapeutics Inc (MSTX)
Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., incorporated in December 1995, is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011, the Company also is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel. The Company offers ANX-188 (purified poloxamer 188), ANX-514 (docetaxel for injectable emulsion) and Exelbine (vinorelbine injectable emulsion). In April 2011, the Company acquired SynthRx, Inc. In February 2014, Mast Therapeutics Inc completed its acquisition of Aires Pharmaceuticals, Inc. Aires became a wholly-owned subsidiary of Mast Therapeutics.
ANX-188 (purified poloxamer 188)
ANX-188 is an aqueous solution of a purified form of poloxamer 188. Poloxamer 188 (P1880, is a nonionic, block copolymer that has been found to improve microvascular blood flow by reducing viscosity, particularly under low shear conditions, and by reducing adhesive frictional forces. The Company�� purified form of P188 (purified P188), which is the active ingredient in ANX-188, was designed to eliminate certain low molecular weight substances present in P188 (non-purified), which is primarily responsible for the moderate to moderately severe elevations in serum creatinine levels (acute renal dysfunction) observed in prior clinical studies of P188 (non-purified). Purified P188 has been evaluated in multiple clinical studies by a prior sponsor, including a 255-patient, phase III study.
ANX-514 (docetaxel for injectable emulsion)
ANX-514 is a detergent-free emulsion formulation of docetaxel, an intravenously-injected chemotherapy drug commonly used to treat solid tumors. Taxotere, a branded form! ulation of docetaxel, is approved to treat breast, non-small cell lung, prostate, gastric, and head and neck cancers. ANX-514 was designed to have clinically comparable release of docetaxel relative to Taxotere while eliminating the presence of polysorbate 80 and ethanol, both of which are used to solubilize docetaxel in the Taxotere formulation. The ANX-514 formulation solubilizes docetaxel using oil droplets consists of a combination of non-toxic excipients. Docetaxel is contained within these oil droplets and can be administered intravenously without using detergents as pharmaceutical vehicles. Once in central circulation, the emulsion is metabolized rapidly, leaving chemically-identical active ingredient to exert its cytotoxic effect. ANX-514 may reduce the incidence and severity of hypersensitivity reactions and delay the onset of fluid retention.
Exelbine (vinorelbine injectable emulsion)
Exelbine is an emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the United States to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer.
In August 2011, the Company received a complete response letter from the Food and Drug Administration (FDA) stating that it could not approve the Exelbine Non Disclosure Agreement (NDA) in its present form and that the bioequivalence study would need to be repeated because the authenticity of the drug products used in the bioequivalence trial could not be verified in accordance with FDA standards. However, the Company elected to discontinue independent development of Exelbine and as of December 31, 2011, the Company was seeking a partner or outside investor for the program to complete the necessary bioequivalence study.
The Company competes with GlaxoSmithKline, Provenge and Pfizer.
Advisors' Opinion:- [By James E. Brumley]
A little over a month ago, owning Mast Therapeutics, Inc. (NYSE: MSTX) was nothing but pure misery. Shares plunged from $0.63 to $0.43 in one day, when details of a dilutive public offering were unveiled. As is so often the case though, the market may have overshot with the selling effort that KO's MSTX. Though putting more shares 'out there' mathematically meant existing shareholders would have to share more of the company's upside with newcomers, what's slowly coming to light is that the inflow of new cash is still more advantageous to those prior shareholders; the company would progress little without it.
- [By Lauren Pollock]
Mast Therapeutics Inc.(MSTX) said the U.S. Food and Drug Administration gave orphan-drug designation to its MST-188 drug for the treatment of acute limb ischemia, providing a boost for the biopharmaceutical firm. Shares surged.
- [By Roberto Pedone]
Mast Therapeutics (MSTX), a biopharmaceutical company, focuses on developing therapies for serious or life-threatening diseases. This stock closed up 2.1% 65 cents per share in Thursday's trading session.
Thursday's Range: $0.63-$0.67
52-Week Range: $0.40-$1.10
Thursday's Volume: 1.11 million
Three-Month Average Volume: 1.88 millionFrom a technical perspective, MSTX spiked modestly higher here right above its 50-day moving average of 61 cents per share with decent upside volume. This stock has been trending sideways and consolidating for the last month, with shares moving between 60 cents on the downside and 72 cents on the upside. Shares of MSTX are now starting to push higher and into range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern. That trade will hit if MSTX manages to clear some near-term overhead resistance levels at 68 to 72 cents per share with high volume.
Traders should now look for long-biased trades in MSTX as long as it's trending above some key near-term support at 60 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.88 million shares. If that breakout materializes soon, then MSTX will set up to re-test or possibly take out its next major overhead resistance levels at 80 to 85 cents per share, or even 93 cents per share.
- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
Top 5 Oil Service Companies For 2015: Addus HomeCare Corporation(ADUS)
Addus HomeCare Corporation provides a range of social and medical services to individuals in the home. The company serves individuals with special needs who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill, and disabled. It offers various health services that include personal care and assistance with activities of daily living, skilled nursing and rehabilitative therapies, and adult day care. The company?s Home and Community Services division offers assistance with bathing, grooming, dressing, personal hygiene and medication reminders, and other activities of daily living on a long-term, continuous basis, with an average duration of 20 months per consumer. Its Home Health Services division comprises physical, occupational, and speech therapy, as well as skilled nursing services, which are offered on a short-term, intermittent, or episodic basis to individuals recovering from an acute medical condition, with an average length of care of 80 days. The company?s payor clients include federal, state, and local government programs, such as Medicaid funded programs and Medicaid waiver programs; other state agencies and Medicare; and the Veterans Health Administration, commercial insurers, and private duty consumers. The company was formerly known as Addus Holding Corporation and changed its name to Addus HomeCare Corporation in September, 2006. Addus HomeCare Corporation was incorporated in 2006 and is headquartered in Palatine, Illinois.
Advisors' Opinion:- [By Monica Gerson]
Addus HomeCare (NASDAQ: ADUS) is projected to post its Q4 earnings at $0.25 per share on revenue of $68.07 million.
magicJack VocalTec (NASDAQ: CALL) is expected to post its Q4 earnings at $0.41 per share on revenue of $35.93 million.
No comments:
Post a Comment